Evidence map›Paper›PMID 33080942›Full record

ReviewAnimals : an open access journal from MDPI2020

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction.

Christopher J Charles, Miriam T Rademaker, Nicola J A Scott, A Mark Richards

Abstract readReview
In one paragraph

Review in Animals : an open access journal from MDPI, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Soft robotic devices for cardiovascular medicine.Nature reviews. Cardiology · 2026
    Review
  2. Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Early- to mid-gestational testosterone excess leads to adverse cardiac outcomes in postpartum sheep.American journal of physiology. Heart and circulatory physiology · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Circulating sphingolipids in heart failure.Frontiers in cardiovascular medicine · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher J CharlesChristchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, Christchurch 8011, New Zealand.ORCID 0000-0001-9807-8022
Miriam T RademakerChristchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, Christchurch 8011, New Zealand.
Nicola J A ScottChristchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, Christchurch 8011, New Zealand.
A Mark RichardsChristchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, Christchurch 8011, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is the final common end point of multiple metabolic and cardiovascular diseases and imposes a significant health care burden worldwide. Despite significant improvements in clinical management and outcomes, morbidity and mortality remain high and there remains an indisputable need for improved treatment options. The pathophysiology of HF is complex and covers a spectrum of clinical presentations from HF with reduced ejection fraction (HFrEF) (≤40% EF) through to HF with preserved EF (HFpEF), with HFpEF patients demonstrating a reduced ability of the heart to relax despite an EF maintained above 50%. Prior to the last decade, the majority of clinical trials and animal models addressed HFrEF. Despite growing efforts recently to understand underlying mechanisms of HFpEF and find effective therapies for its treatment, clinical trials in patients with HFpEF have failed to demonstrate improvements in mortality. A significant obstacle to therapeutic innovation in HFpEF is the absence of preclinical models including large animal models which, unlike rodents, permit detailed instrumentation and extensive imaging and sampling protocols. Although several large animal models of HFpEF have been reported, none fulfil all the features present in human disease and few demonstrate progression to frank decompensated HF. This review summarizes well-established models of HFrEF in pigs, dogs and sheep and discusses attempts to date to model HFpEF in these species.

Indexed as

animal modelejection fractionheart failureHFpEFHFrEFovineporcine

Identifiers

PMID33080942
PMCPMC7603281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.